Umbrella review of the efficacy of perioperative immunonutrition in visceral surgery.

Immunonutrition Infection Postoperative complication Visceral surgery meta-Analysis

Journal

Clinical nutrition ESPEN
ISSN: 2405-4577
Titre abrégé: Clin Nutr ESPEN
Pays: England
ID NLM: 101654592

Informations de publication

Date de publication:
04 2022
Historique:
received: 11 02 2022
accepted: 16 02 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 31 3 2022
Statut: ppublish

Résumé

Immunonutrition (IN) is used in major visceral surgery to reduce postoperative complications. This umbrella review (review of reviews) collects and analyses data on the efficacy of perioperative IN. The review was conducted in accordance with PRISMA 2020 guidelines. Inclusion criteria were meta-analyses comparing IN with normal diet or isocaloric isonitrogenous feeding. The primary outcome was infectious complications. Secondary outcomes were overall morbidity, hospital length of stay and mortality. Methodological quality was evaluated using AMSTAR-2. Overlap and certainty of evidence (GRADE) were assessed. Twenty meta-analyses (MAs) were included in the umbrella review: eleven on various abdominal surgeries (one MA was considered twice) and eight on pancreatic, oesophageal, hepatic, or colorectal surgeries. Overall, IN was associated with significantly fewer postoperative infectious complications (OR 0.60 [0.54-0.65], random effect model) but with substantial heterogeneity (I This umbrella review confirms the beneficial effect of IN in visceral surgery. Some practical questions remain unanswered: optimal timing of IN, in which surgical speciality it is best used, and its utility in enhanced recovery programmes. CRD42021255177.

Identifiants

pubmed: 35331540
pii: S2405-4577(22)00064-X
doi: 10.1016/j.clnesp.2022.02.015
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

99-108

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest K Slim declares competing interests with Sanofi, Merck, B-Braun, Viatris and Coloplast. No competing interest for the other authors.

Auteurs

K Slim (K)

Department of Digestive Surgery, University Hospital CHU Clermont-Ferrand, France; Francophone Group for Enhanced Recovery After Surgery (GRACE), France. Electronic address: kslim@chu-clermontferrand.fr.

F Badon (F)

Department of Digestive Surgery, University Hospital CHU Clermont-Ferrand, France.

C H Vacheron (CH)

Department of Anaesthesiology, Anaesthesia and Intensive Care, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France; Department of Biostatistics, Hospices Civils de Lyon, Lyon, France; CIRI, Centre International de Recherche en Infectiologie (Equipe Laboratoire des Pathogènes Emergents), Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Lyon, France.

B V Occean (BV)

Department of Statistics, University Hospital, Nîmes, France.

C Dziri (C)

Tunis University El Manar - Medical School of Tunis, Tunisia; Director of Honoris Medical Simulation Center - Tunis, Tunisia.

C Chambrier (C)

Department of Nutrition, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH